Kimball Electronics (3C3) Q4 2026 Earnings Report

The call was largely constructive: management highlighted stabilization of the base business, strong cash generation, meaningful balance sheet improvement, gross margin expansion, and an accretive acquisition (Helvoet) that supports FY2027 growth guidance of 7%–9%. Medical continues to be the primary growth engine. Offsetting these positives are persistent weakness in Automotive and Industrial segments, near-term margin pressure from ramping the Indianapolis CDMO facility (an estimated ~$6.5M–$7M drag), a very high Q4 effective tax rate that distorted adjusted results, and expected working capital headwinds and FX translation risk associated with Helvoet. Overall, the positives (cash, guidance, Medical momentum, acquisition synergies, and improved margins/interest costs) outweigh the negatives, though several risks remain in the near term.

Guidance for fiscal 2027 calls for net sales of $1.535–$1.56 billion (up 7%–9% vs. FY2026) comprising 3%–5% organic growth plus roughly $60 million of Helvoet revenue, with Medical expected to approach ~35% of company sales and deliver high-single to low-double digit organic growth, Industrial roughly in line with the company average, and Automotive essentially flattish; adjusted operating income is forecast at 4.4%–4.7% of sales, capital expenditures $50–$60 million, an effective tax rate in the low‑30s, and revenue fairly evenly distributed quarter-to-quarter, while management expects the Indianapolis ramp to create roughly a $6.5–$7.0 million drag (production beginning late calendar year with an ~18‑month move completion) largely offset by Helvoet accretion — all against a balance sheet with $88.9 million cash, $116.6 million borrowings (lowest in >4 years), $411.3 million of short‑term liquidity, $72.3 million of FY26 operating cash flow, and $24.4 million remaining on the share‑repurchase authorization.